Providence Swedish Radiosurgery Center in Seattle Invests in Second Accuray CyberKnife® System, a Robotic Delivery Device That Makes Extremely Precise Radiation Treatments Possible in 1-5 Sessions

New System Will Play a Key Role in Delivering Radiation Treatments in One of the Largest Cancer Facilities in Washington State

Accuray CyberKnife® System

Accuray Incorporated (NASDAQ: ARAY) announced today that the Providence Swedish Radiosurgery Center in Seattle, Washington is enhancing its cancer treatment capabilities with the purchase of the latest generation CyberKnife® S7™ System, the hospital’s second CyberKnife radiation delivery device purchase.

Precision and Accuracy

The precision and accuracy enabled by the system’s robotic design will also make it an ideal choice for the treatment of neurologic disorders. The new system will enable the medical team to deliver gold standard stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT) treatments faster than with previous models, expanding access to an effective and convenient option to more patients.

First Use at

“The Providence Swedish Radiosurgery Center began using their first CyberKnife System more than 10 years ago. Since then, we’ve built a valuable partnership based on our mutual goal to transform the cancer patient experience with technologies that improve patient comfort during treatment and extend both survivorship and quality of life post-treatment,” said Suzanne Winter, President and CEO of Accuray. “I couldn’t be prouder that the Providence Swedish Radiosurgery team is continuing to invest in Accuray technologies. It signifies their confidence in our company, our people and our products.”

Non-invasive Radiation Therapy Device

The CyberKnife S7 System is a non-invasive radiation therapy device that was built from the ground-up to provide clinicians with the speed they need for operational efficiency without sacrificing the precision and accuracy required for stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT). The system uses artificial intelligence (AI) to track and automatically adapt for tumor or patient movement during treatment, delivering the radiation dose directly to the target with sub-millimeter precision – in as little as 15 minutes.

Dr. Christopher Loiselle, Executive Medical Director, Providence Swedish Radiosurgery Center and President of the Tumor Institute Radiation Oncology Group

“At Providence Swedish Radiosurgery Center, we recognize that treatment decisions significantly impact patients’ immediate health and long term quality of life. Our top priority is to provide excellent care for each person who walks through our door, leveraging the latest innovations in radiation therapy technologies and techniques to improve patient outcomes. We have had a successful experience with the CyberKnife System and a positive relationship with the Accuray team. We purchased the CyberKnife S7 device because we are confident the system will further our ability to meet our patient-centered treatment goals.”

Significant Contributions

The Providence Swedish Radiosurgery Center team has made significant contributions to the field of radiation medicine including leading the first large, multi-center clinical trial with long-term follow-up evaluating the use of SBRT in prostate cancer delivered by the CyberKnife System. They also are actively involved in research assessing the use of SBRT to treat tumors in other areas of the body and radiosurgery in the treatment of cancer and medical conditions in the brain.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version